170 related articles for article (PubMed ID: 38172600)
1. Spatial architectures of somatic mutations in normal prostate, benign prostatic hyperplasia and coexisting prostate cancer.
Chae J; Jung SH; Choi EJ; Kim JW; Kim NY; Moon SW; Lee JY; Chung YJ; Lee SH
Exp Mol Med; 2024 Feb; 56(1):168-176. PubMed ID: 38172600
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.
White JA; Kaninjing ET; Adeniji KA; Jibrin P; Obafunwa JO; Ogo CN; Mohammed F; Popoola A; Fatiregun OA; Oluwole OP; Thorpe RJ; Karanam B; Elhussin I; Ambs S; Tang W; Davis M; Polak P; Campbell MJ; Brignole KR; Rotimi SO; Dean-Colomb W; Odedina FT; Yates C
Prostate; 2024 Apr; 84(5):460-472. PubMed ID: 38192023
[TBL] [Abstract][Full Text] [Related]
3. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.
Buhigas C; Warren AY; Leung WK; Whitaker HC; Luxton HJ; Hawkins S; Kay J; Butler A; Xu Y; Woodcock DJ; Merson S; Frame FM; Sahli A; Abascal F; ; Martincorena I; Bova GS; Foster CS; Campbell P; Maitland NJ; Neal DE; Massie CE; Lynch AG; Eeles RA; Cooper CS; Wedge DC; Brewer DS
Mol Cancer; 2022 Sep; 21(1):183. PubMed ID: 36131292
[TBL] [Abstract][Full Text] [Related]
4. Organ-wide telomeric status in diseased and disease-free prostatic tissues.
Heaphy CM; Fleet TM; Treat EG; Lee SJ; Smith AY; Davis MS; Griffith JK; Fischer EG; Bisoffi M
Prostate; 2010 Sep; 70(13):1471-9. PubMed ID: 20687220
[TBL] [Abstract][Full Text] [Related]
5. p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer.
Schlechte H; Lenk SV; Löning T; Schnorr D; Rudolph BD; Ditscherlein G; Loening SA
Eur Urol; 1998; 34(5):433-40. PubMed ID: 9803007
[TBL] [Abstract][Full Text] [Related]
6. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
[TBL] [Abstract][Full Text] [Related]
7. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
8. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
[TBL] [Abstract][Full Text] [Related]
9. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
Zambra FM; Biolchi V; Brum IS; Chies JA
Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma.
Royuela M; De Miguel MP; Bethencourt FR; Sanchez-Chapado M; Fraile B; Paniagua R
Growth Factors; 1998; 16(2):101-10. PubMed ID: 9932228
[TBL] [Abstract][Full Text] [Related]
11. No Tumor Suppressor Role for
Koseoglu H; Celebi A; Galamiyeva G; Dalay N; Ozkardes H; Buyru N
DNA Cell Biol; 2021 Sep; 40(9):1222-1229. PubMed ID: 34370601
[TBL] [Abstract][Full Text] [Related]
12. Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review.
Al-Khalil S; Boothe D; Durdin T; Sunkara S; Watkins P; Yang S; Haynes A; de Riese W
Int Urol Nephrol; 2016 Jan; 48(1):91-7. PubMed ID: 26590832
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte Telomere Length and the Risk of Prostate Cancer and Benign Prostatic Hyperplasia: Insights From UK Biobank and Mendelian Randomization Study.
Lv K; Wu Y; Yang G; Hao X; Huang S; Song T; Yuan Q
J Gerontol A Biol Sci Med Sci; 2024 Mar; 79(3):. PubMed ID: 38085929
[TBL] [Abstract][Full Text] [Related]
15. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
16. Differential growth factor responses of epithelial cell cultures derived from normal human prostate, benign prostatic hyperplasia, and primary prostate carcinoma.
Chopra DP; Grignon DJ; Joiakim A; Mathieu PA; Mohamed A; Sakr WA; Powell IJ; Sarkar FH
J Cell Physiol; 1996 Nov; 169(2):269-80. PubMed ID: 8908194
[TBL] [Abstract][Full Text] [Related]
17. PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.
Koch P; Petri M; Paradowska A; Stenzinger A; Sturm K; Steger K; Wimmer M
Prostate; 2009 Dec; 69(16):1751-62. PubMed ID: 19691131
[TBL] [Abstract][Full Text] [Related]
18. Association between prostate size and glandular tissue volume of the peripheral zone via novel combined MRI and histopathology: possible pathophysiological implications on prostate cancer development.
Lin B; Cavdar IK; Buxton M; Sellers J; Brandi L; Helo N; de Riese WTW
Int Urol Nephrol; 2023 Apr; 55(4):835-844. PubMed ID: 36739353
[TBL] [Abstract][Full Text] [Related]
19. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma.
Cordon-Cardo C; Koff A; Drobnjak M; Capodieci P; Osman I; Millard SS; Gaudin PB; Fazzari M; Zhang ZF; Massague J; Scher HI
J Natl Cancer Inst; 1998 Sep; 90(17):1284-91. PubMed ID: 9731735
[TBL] [Abstract][Full Text] [Related]
20. Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis.
Middleton LW; Shen Z; Varma S; Pollack AS; Gong X; Zhu S; Zhu C; Foley JW; Vennam S; Sweeney RT; Tu K; Biscocho J; Eminaga O; Nolley R; Tibshirani R; Brooks JD; West RB; Pollack JR
JCI Insight; 2019 May; 5(12):. PubMed ID: 31094703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
